Advertisement

Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B

  • F. Wei
  • S.-K. Liu
  • X.-Y. Liu
  • Z.-J. Li
  • B. Li
  • Y.-L. Zhou
  • H.-Y. Zhang
  • Y.-W. Li
Article

Abstract

Silymarin is used by many patients with chronic hepatitis B, but its efficacy remains unknown. The aim of this investigation was to conduct a meta-analysis to determine the efficacy and safety of silymarin and its combination therapy for the treatment of chronic hepatitis B. We searched Chinese and English reports from January 1966 to December 2011, using 12 databases. Two reviewers independently screened all reports to identify randomized placebo-controlled trials that evaluated silymarin and its combination therapy for the treatment of chronic hepatitis B. Twelve trials satisfied the eligibility criteria for this meta-analysis. Silymarin was equivalent to antiviral drug or protection liver drugs in serum transaminases, viral load and hepatic fibrosis markers. But silymarin combined with antiviral drug or antiviral drug and protection liver drugs significantly reduced the level of serum transaminases, hepatic fibrosis markers and serum TGF-β1, TNF-α, IL-6 versus antiviral drug or protection liver drugs. Silymarin combined with protection liver drugs significantly reduced the level of serum transaminases, TBIL, hepatic fibrosis markers and was equivalent to protection liver drugs in the normalisation rates of serum transaminases, TBIL, but protection liver drugs significantly increased the improvement rates of hepatic fibrosis markers. Silymarin combined with antiviral drug or antiviral drug and protection liver drugs may have potential therapeutic value. Treatment with silymarin appears to be safe and well tolerated. The data are too limited to exclude a substantial benefit or harm of silymarin and its combination therapy on serum transaminases, and also to support recommending this herbal compound for the treatment of chronic hepatitis B.

Keywords

Chronic Hepatitis Antiviral Drug Silymarin Weighted Mean Difference Silibinin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

We have no financial relationship with the College of Pharmacy, Central South University, who sponsored the research. The authors declare that we have no conflict of interest.

Supplementary material

10096_2012_1789_MOESM1_ESM.docx (48 kb)
ESM 1 (DOCX 47 kb)

References

  1. 1.
    Rambaldi A, Jacobs BP, Iaquinto G et al (2005) Milk thistle for alcoholic and/or hepatitis B or C liver diseases—a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 100:2583–2591PubMedCrossRefGoogle Scholar
  2. 2.
    Loguercio C, Festi D (2011) Silybin and the liver: from basic research to clinical practice. World J Gastroenterol 17(18):2288–2301PubMedCrossRefGoogle Scholar
  3. 3.
    Schulz V, Hansel R, Tyler VE (1998) Rational phytotherapy: a physician’s guide to herbal medicine, 3rd edn. Springer, Berlin, p 306CrossRefGoogle Scholar
  4. 4.
    Boigk G, Stroedter L, Herbst H et al (1997) Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26:643–649PubMedCrossRefGoogle Scholar
  5. 5.
    Muriel P, Garciapiña T, Perez-Alvarez V et al (1992) Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol 12:439–442PubMedCrossRefGoogle Scholar
  6. 6.
    Halim AB, el-Ahmady O, Hassab-Allah S et al (1997) Biochemical effect of antioxidants on lipids and liver function in experimentally-induced liver damage. Ann Clin Biochem 34(Pt 6):656–663PubMedGoogle Scholar
  7. 7.
    Haková H, Mišúrová E (1993) The effect of silymarin and gamma radiation on nucleic acids in rat organs. J Pharm Pharmacol 45:910–912CrossRefGoogle Scholar
  8. 8.
    Comoglio A, Tomasi A, Malandrino S et al (1995) Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. Biochem Pharmacol 50:1313–1316PubMedCrossRefGoogle Scholar
  9. 9.
    de Groot H, Dehmlow C, Raven U (1996) Tissue injury by free radicals and the protective effects of flavonoids. Methods Find Exp Clin Pharmacol 18(Suppl B):23–25PubMedGoogle Scholar
  10. 10.
    Flora K, Hahn M, Rosen H et al (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93:139–143PubMedCrossRefGoogle Scholar
  11. 11.
    Morazzoni P, Bombardelli E (1995) Silybum marianum (Carduus marianus). Fitoterapia 66:3–42Google Scholar
  12. 12.
    Jacobs BP, Dennehy C, Ramirez G et al (2002) Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 113:506–515PubMedCrossRefGoogle Scholar
  13. 13.
    Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRefGoogle Scholar
  14. 14.
    Lu H-Y (2009) The curative effect of compound liver-benepitino remedy treating chronic hepatitis B. J Changchun Univ Tradit Chin Med 5:710–711Google Scholar
  15. 15.
    Ding S-G, Zhang Z-Q (2003) The curative effect of legalon treating 39 cases of chronic hepatitis B. Shandong Med 16:44Google Scholar
  16. 16.
    Hou S-R, Zhou D-H, Bai H et al (2000) Estimating the therapeutic effect of silymarin treating chronic hepatitis B. Jiangsu Med J 6:437–438Google Scholar
  17. 17.
    Zhu Y-K, Duan Z-P, Wang B-E et al (2009) To observe the curative effect of silibinin phosphatidylcholine complex treating chronic hepatitis B. Chinese J Clin Pharmacol Ther 14:1392–1395Google Scholar
  18. 18.
    Wang Z-F, Meng X-F (2006) To observe the curative effect of silymarin treating chronic hepatitis B. Chinese J Clin Med Res 151:30–31Google Scholar
  19. 19.
    Bao F-Y, Xie J (2006) Silibinin phospholipid complex combined with interferon treating hepatitis B. Cent Plains Med J 15:70–71Google Scholar
  20. 20.
    Xie Y-M (2006) Evaluation of silymarin in the treatment of chronic hepatitis B. Chinese J New Drugs 9:725–727Google Scholar
  21. 21.
    Li H, Zou H-B, Lu C-Z et al (2005) Treatment of chronic hepatitis B with silibinin capsules. Chinese J New Drugs 5:621–623Google Scholar
  22. 22.
    Huo Y-K, Chu F, Pei B (2009) To observe the effect in treating chronic hepatitis B with silybin meglumine combined with hepatocyte growth-promoting factors. Public Health Clin Med 4:274–276Google Scholar
  23. 23.
    Peng M-S (2010) To observe the effect in treating chronic hepatitis with silybin. China Mod Med 7:42–43Google Scholar
  24. 24.
    Yu C-Y, Dong Y-L (2011) To observe the effect in treating hepatic fibrosis of chronic hepatitis B with silybin and danshen root. Chinese Commun Dr 7:13Google Scholar
  25. 25.
    Bao F-Y, Tan Y-W (2009) Effect of silybin compound on fibrosis indexes and cytokines in patients with hepatitis B. China Health Care Nutr 12:51–52Google Scholar
  26. 26.
    McCulloch M, Broffman M, Gao J et al (2002) Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomized, controlled trials. Res Pract 92:1619–1628Google Scholar
  27. 27.
    Gou W, Wang Y-L (2004) To observe the effect of interferon α-2b combined with silymarin to treat chronic hepatitis B. J Clin Hepatol 5:302Google Scholar
  28. 28.
    Bao F-Y, Qiu P-Y (2006) Analyzing the adjunctive therapy of silibinin phospholipid complex treat chronic hepatitis B in 86 cases. Shandong Med 26:31Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • F. Wei
    • 1
    • 2
  • S.-K. Liu
    • 1
    • 2
  • X.-Y. Liu
    • 3
  • Z.-J. Li
    • 1
    • 2
  • B. Li
    • 2
  • Y.-L. Zhou
    • 2
  • H.-Y. Zhang
    • 4
  • Y.-W. Li
    • 5
  1. 1.Pharmaceutics DepartmentCollege of Pharmacy, Central South UniversityChangshaChina
  2. 2.Department of PharmacyThe Third Xiangya Hospital of Central South UniversityChangshaChina
  3. 3.Department of PharmacyThe First Affiliated Hospital of Gannan Medical UniversityGanzhouChina
  4. 4.Infectious Diseases DepartmentThe Third Xiangya Hospital of Central South UniversityChangshaChina
  5. 5.Department of AnesthesiologyThe Third Xiangya Hospital of Central South UniversityChangshaChina

Personalised recommendations